Phase 2a trial

COPENHAGEN, Denmark, July 28, 2026 Antag Therapeutics announced that the first patient has been dosed in its Phase 2a...

SARASOTA, Fla., July 15, 2026 Lakewood-Amedex Biotherapeutics Inc. has announced encouraging preclinical safety results supporting dose selection for the...

MENLO PARK, California, July 13, 2026 PharmatrophiX, in collaboration with Indiana University School of Medicine, has presented encouraging new...

MIAMI, July 13, 2026 Longeveron announced new analyses from its Phase 2a CLEAR MIND clinical trial demonstrating that its...

AARHUS, Denmark, June 17, 2026 NMD Pharma A/S announced new positive clinical findings from its Phase 2a SYNAPSE-CMT study...

VANCOUVER, Wash., June 11, 2026 CytoDyn Inc. announced that the first patient has been dosed in the Phase 2a...

AUSTIN, Texas, June 9, 2026 Zetagen Therapeutics announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™...

LUND, Sweden, May 27, 2026 Hansa Biopharma AB has announced positive topline results from its European Post Authorization Efficacy...

BOSTON, May 27, 2026 TransCode Therapeutics, Inc., a clinical-stage biotechnology company focused on RNA-based cancer therapeutics, has announced the...

NEW YORK, United States – May 5, 2026 Hoth Therapeutics, Inc. has announced that it secured regulatory authorization in...